Helicobacter pylori infection impact on long-term prognosis in patients implanted with drug-eluting stent with acute coronary syndrome

doi:10.3969/j.issn.1006-7795.2016.06.006

Abstract

Abstract: Objective To explore the relationship between Helicobacter pylori (Hp) infection and the long-term outcome in patients with acute coronary syndrome (ACS) treated with drug-eluting stent (DES) implantation. Methods We retrospectively analyzed consecutive 326 patients who were treated with DES implantation from January 1, 2010 to December 31, 2012. Demographic data were collected and all patients underwent examination of high sensitivity C-reactive protein (hsCRP), homocysteine (HCY) and other biochemical indicators. All the patients were divided into three groups according to the result of ¹³C urea breath test. Group 1 had 176 patients without Hp infection; Group 2 had 75 patients with Hp infection with eradication therapy; and group 3, 75 patients with Hp infection without eradication therapy. We explored the correlations of Hp infection with major adverse cardiovascular event (MACE) and upper gastrointestinal bleeding (UGIB) after 5 years of follow-up using survival analysis. Results After 5 years of follow-up, we found that patients with Hp infection without therapy had more MACE and UGIB than the other two groups (P value is 0.009 and 0.000, respectively). Survival analysis showed that Hp infection was a predictor of MACE with a hazard ratio (HR) of 2.441, with 95% confidence interval (CI): 1.354-4.400, P=0.003 and UGIB with HR of 5.257, with 95% CI:2.572-10.745, P<0.001. Conclusion Patients after DES implantation with Hp infection had more MACE and UGIB after 5 years of follow-up. Hp eradication therapy maybe able to lower the rate of MACE and UGIB.

Key words: Helicobacter pylori, eradication therapy, acute coronary syndrome, major adverse cardiac events, long-term outcome

CLC Number:

Wang Dezhao, Wang Jun, Li Shijing, Chen Buxing. Helicobacter pylori infection impact on long-term prognosis in patients implanted with drug-eluting stent with acute coronary syndrome[J]. Journal of Capital Medical University, 2016, 37(6): 746-752.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.06.006

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I6/746

References

[1] Budzyński J, Kłopocka M, Bujak R, et al. Autonomic nervousfunction in Helicobacter pylori-infected patients with atypical chest pain studied by analysis of heart rate variability[J]. Eur J Gastroenterol Hepatol, 2004,16(5): 451-457.
[2] Fashner J,Gitu A C. Common gastrointestinal symtoms: dyspepsia and Helicobacter pylori[J]. FP Essent, 2013,413(10): 24-28.
[3] Roesler B M, Rabelo-Gonçalves E M, Zeitune J M.Virulence factors of Helicobacter pylori: a review[J].Clin Med Insights Gastroenterol, 2014,7(3): 9-17.
[4] Ng F H, Wong S Y, Chang C M, et al. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome[J]. Am J Gastroenterol, 2008, 103(4): 865-871.
[5] Huang K W, Luo J C, Huang C C, et al. Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel[J]. J Chin Med Assoc, 2013,76(1):9-14.
[6] Rogha M, Nikvarz M, Pourmoghaddas Z, et al. Is Helicobacter pylori infection a risk factor for coronary heart disease?[J]. ARYA Atheroscler,2012,8(1):5-8.
[7] Vafaeimanesh J, Hejazi S F, Damanpak V, et al. Association of Helicobacter pylori infection with coronary artery disease: is Helicobacter pylori a risk factor?[J].Scientific World Journal,2014,2014:516354.
[8] Lee S Y.Current progress toward eradicating Helicobacter pylori in East Asian countries:differences in the 2013 revised guidelines between China, Japan, and South Korea[J].World J Gastroenterol,2014,20(6):1493-1502.
[9] Hamm C W, Bassand J P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of aute coronary syndromes (ACS) in patients presenting without persistent ST-segement elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2011,32(23): 2999-3054.
[10] 邸岩, 高炳霞, 齐颖, 等. 门诊患者¹³C-呼气试验检测幽门螺杆菌的调查分析[J]. 中华医院感染学杂志, 2013, 23(24): 5960-5962.
[11] Cutlip D E, Windecker S, Mehran R, et al. Clincal end points in coronary stent trials: a case for standardized definitions[J]. Circulation,2007,115(17): 2344-2351.
[12] Celik T, Iyisoy A, Yuksel U C. Possible pathogenetic role of Helicobacter pylori infection in cardiac syndrome X[J]. Int J Cardiol,2010,142(2):193-194.
[13] Assadi M, Saghari M, Ebrahimi A, et al. The relation between Helicobacter pylori infection and cardiac syndrome X: apreliminary study[J].Int J Cardiol,2009,134(3):e124-e125.
[14] Franceschi F, Niccoli G, Ferrante G, et al. CagA antigen of Helicobacter pylori and coronary instability: insight from aclinico-pathological study and a meta-analysis of 4241 cases[J]. Atherosclerosis, 2009,202(2):535-542.
[15] Ozdogru I, Kalay N, Dogan A, et al. The relationship between Helicobacter pylori IgG titre and coronary atherosclerosis[J]. Acta Cardiol, 2007,62(5):501-505.
[16] Saleh N, Svane B, Jensen J, et al. Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris[J]. Am Heart J, 2005, 149(5):876-882.
[17] Delaney B C, Hobbs F D, Holder R. Association of Helicobacter pylori infection with coronary heart disease. Eradication of the infection on grounds of cardiovascular risk is not supported by current evidence[J]. BMJ,1996,312(7025):251-252.
[18] Sessa R, Pietro M D, Filardo S, et al. Infectious burden and atherosclerosis: a clinical issue[J].World J Clin Cases,2014,2(7):240-249.
[19] Tamer G S, Tengiz I, Ercan E, et al. Helicobacter pylori seropositivity in patients with acute coronary syndromes[J]. Dig Dis Sci,2009, 54(6):1253-1256.
[20] Fagoonee S, De Angelis C, Elia C, et al. Potential link betweenHelicobacter pylori and ischemic heart disease: does the bacterium elicit thrombosis?[J]. Minerva Med,2010,101(2):121-125.
[21] Rechciński T, Kasprzak J D, Chmiela M, et al. Patients with unstable angina pectoris present increased humoral response againstHelicobacter pylori in comparison with patients with aggravated dyspepsia[J]. Acta Microbiol Pol,2002,51(4):339-344.
[22] Strachan D P. Non-gastrointestinal consequences of Helicobacter pylori infection[J]. Br Med Bull,1998,54(1):87-93.
[23] Zhu J, Katz R J, Quyyumi A A, et al. Association of serum antibodies to heat-shock protein 65 with coronary calcification levels: suggestion of pathogen-triggered autoimmunity in early atherosclerosis[J]. Circulation,2004,109(1):36-41.
[24] Izadi M, Fazel M, Sharubandi S H, et al. Helicobacter species in the atherosclerotic plaques of patients with coronaryartery disease[J].Cardiovasc Pathol,2012,21(4):307-311.
[25] Smieja M, Gnarpe J, Lonn E, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study[J]. Circulation,2003,107(2):251-257.
[26] Eskandarian R, Ghorbani R, Shiyasi M, et al. Prognostic role of Helicobacter pylori infection in acute coronary syndrome: aprospective cohort study[J].Cardiovasc J Afr, 2012,23(3):131-135.
[27] 李玲, 姜树强,龙丽娟,等. 健康人群幽门螺杆菌感染情况调查分析[J]. 解放军医药杂志,2013,25(10):98-99.